T, O., J, L., C, S., L, Z., & X, G. (2021). Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study. Dove Medical Press.
Cita Chicago Style (17a ed.)T, Ouyang, Liu J, Shi C, Zhu L, y Guo X. Drug-Eluting Bead Transarterial Chemoembolization Versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study. Dove Medical Press, 2021.
Cita MLA (8a ed.)T, Ouyang, et al. Drug-Eluting Bead Transarterial Chemoembolization Versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study. Dove Medical Press, 2021.